Our in vitro data suggests that combination inhibition of RAF and MEK with sorafenib/AZ628 and selumetinib, respectively, should be further explored as a potential approach for inhibiting tumor growth in non-V600 BRAF mutant malignancies. Here, MAP2K7 is linked to neoplasm.